Gossamer Bio

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced enrollment completion for the ongoing, global registrational Phase 3 PROSERA Study evaluating seralutinib in Functional Class II and III PAH patients. Gossamer Bio and t.» Mehr auf businesswire.com

Squarepoint Ops LLC trimmed its stake in Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) by 51.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 71,944 shares of the company’s stock after selling 75,013 shares during the period. Squarepoint Ops LLC’s holdings in Gossamer Bio were worth $65,000 at the end of the most recent reporting period. Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GOSS. Two Sigma Investments LP grew its position in shares of Gossamer Bio by 41.3% in the fourth quarter. Two Sigma Investments LP now owns 891,279 shares of the company’s stock valued at $806,000 after purchasing an additional 260,318 shares during the last quarter. Two Sigma Advisers LP grew its holdings in Gossamer Bio by 44.7% in the 4th quarter. Two Sigma Advisers LP now owns 1,157,500 shares of the company’s stock valued at $1,047,000 after buying an additional 357,500 shares during the last quarter. Octagon Capital Advisors LP grew its holdings in Gossamer Bio by 99.7% in the 4th quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company’s stock valued at $16,599,000 after buying an additional 9,162,117 shares during the last quarter. Millennium Management LLC grew its holdings in Gossamer Bio by 14.6% in the 4th quarter. Millennium Management LLC now owns 3,586,067 shares of the company’s stock valued at $3,244,000 after buying an additional 457,179 shares during the last quarter. Finally, Lazard Asset Management LLC grew its holdings in Gossamer Bio by 7,992.6% in the 4th quarter. Lazard Asset Management LLC now owns 107,470 shares of the company’s stock valued at $97,000 after buying an additional 106,142 shares during the last quarter. 81.23% of the stock is currently owned by institutional investors and hedge funds. Gossamer Bio Price Performance Shares of GOSS stock opened at $1.25 on Wednesday. Gossamer Bio, Inc. has a 12-month low of $0.51 and a 12-month high of $1.55. The firm has a market capitalization of $284.13 million, a price-to-earnings ratio of -3.91 and a beta of 1.85. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. The firm has a fifty day moving average of $1.03 and a 200-day moving average of $1.04. Gossamer Bio (NASDAQ:GOSS – Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. The business had revenue of $9.89 million for the quarter, compared to the consensus estimate of $3.95 million. On average, equities research analysts forecast that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year. Wall Street Analysts Forecast Growth GOSS has been the topic of a number of recent research reports. The Goldman Sachs Group lifted their target price on Gossamer Bio from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, May 16th. Wedbush reissued an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research report on Friday, May 16th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a research report on Tuesday, March 18th. Check Out Our Latest Report on GOSS About Gossamer Bio (Free Report) Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. See Also Five stocks we like better than Gossamer Bio How to Profit From Growth Investing AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway High Dividend REITs: Are They an Ideal Way to Diversify? Casey’s Surges on Strong Q4, More Gains Likely Ahead What Are Dividend Achievers? An Introduction Government Mandate Sends eVTOL Stocks Flying Want to see what other hedge funds are holding GOSS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report).» Mehr auf defenseworld.net

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective June 5th, 2025, to three non-executive employees of non-qualified stock op.» Mehr auf businesswire.com